My Cart
You have no items in your shopping cart.
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
G288292-2mg | 2mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
G288292-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $119.90 | |
G288292-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $209.90 | |
G288292-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $419.90 |
Potent human fatty acid synthase (hFASN) inhibitor
Synonyms | SCHEMBL2356163 | CAS_80220 | CS-3324 | GSK2194069, >=97% (HPLC) | Q27252830 | 4-[4-(1-benzofuran-5-yl)phenyl]-3-{[(3S)-1-cyclopropanecarbonylpyrrolidin-3-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one | NCGC00387475-02 | 1332331-08-4 | 2W4 | 4-[4-(1-benzof |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | Potent human fatty acid synthase (hFASN) inhibitor (IC50= 7.7 nM); inhibits hFASβ-ketoacyl reductase activity. Inhibits lipid synthesis and attenuates proliferation of A549 non-small-cell lung cancer cells (EC50= 15 nM)in vitro. |
Storage Temp | Store at 2-8°C |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of fatty acid synthase |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 4-[4-(1-benzofuran-5-yl)phenyl]-3-[[(3S)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl]methyl]-1H-1,2,4-triazol-5-one |
---|---|
INCHI | InChI=1S/C25H24N4O3/c30-24(18-1-2-18)28-11-9-16(15-28)13-23-26-27-25(31)29(23)21-6-3-17(4-7-21)19-5-8-22-20(14-19)10-12-32-22/h3-8,10,12,14,16,18H,1-2,9,11,13,15H2,(H,27,31)/t16-/m0/s1 |
InChi Key | AQTPWCUIYUOEMG-INIZCTEOSA-N |
Canonical SMILES | C1CC1C(=O)N2CCC(C2)CC3=NNC(=O)N3C4=CC=C(C=C4)C5=CC6=C(C=C5)OC=C6 |
Isomeric SMILES | C1CN(C[C@@H]1CC2=NNC(=O)N2C3=CC=C(C=C3)C4=CC5=C(C=C4)OC=C5)C(=O)C6CC6 |
PubChem CID | 67376285 |
Molecular Weight | 428.48 |
Find and download the COA for your product by matching the lot number on the packaging.
8 results found
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2426164 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426165 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426166 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426167 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426168 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426169 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426170 | Certificate of Analysis | Apr 17, 2024 | G288292 |
G2426171 | Certificate of Analysis | Apr 17, 2024 | G288292 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 42.85, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 8.57, Max Conc. mM: 20 |
---|
Pictogram(s) | GHS06 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed |
Precautionary Statements | P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P316:IF SWALLOWED: Get emergency medical help immediately. |
Starting at $147.90
Starting at $198.90
1. Hardwicke MA, Rendina AR, Williams SP, Moore ML, Wang L, Krueger JA, Plant RN, Totoritis RD, Zhang G, Briand J et al.. (2014) A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.. Nat Chem Biol, 10 (9): (774-9). [PMID:25086508] [10.1021/op500134e] |